Brian M.J. Cantwell

Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer

Rudolf Steiner, John F. Stewart, Brian M.J. Cantwell et al. · European Journal of Cancer and Clinical Oncology · 1983 · 67 citations

Advanced Breast Cancer, Breast Oncology, Medicine +6

Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance

Michael Millward, Brian M.J. Cantwell, Ernst A. Lien et al. · European Journal of Cancer · 1992 · 64 citations

Drug Resistance Analysis, Intermittent High-dose Tamoxifen, Pharmacology +7

Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer

Brian M.J. Cantwell, Valentine M. Macaulay, Adrian L. Harris et al. · European Journal of Cancer and Clinical Oncology · 1988 · 47 citations

Cb 3717, Breast Oncology, Oncology +10

The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16–213, doxorubicin and vincristine (VPAV) for small cell lung cancer

Brian M.J. Cantwell, J.M. Bozzino, Paul A. Corris et al. · European Journal of Cancer and Clinical Oncology · 1988 · 44 citations

Cross Resistance, Oncology, Multidrug Resistant Phenotype +11

A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma

James Carmichael, Brian M.J. Cantwell, Adrian L. Harris · European Journal of Cancer and Clinical Oncology · 1989 · 31 citations

Surgical Oncology, Phase Ii Trial, Malignant Mesothelioma +8